Overall, incidence rates of HR-negative and ERBB2-positive breast cancer increased 2.9% per year from 2010 to 2015 and then decreased 2.9% per year from 2015 to 2019, with a similar pattern observed across all age groups (Figure 5). Here, ERBB2 is linked to breast cancer.